INTRODUCTION
Gentamicin is an aminoglycoside antibacterial used for the treatment of septicemia and other serious infections (1) . A limitation of its use is the narrow therapeutic index and its propensity to induce nephrotoxicity (2) . Nephrotoxicity is often associated with poor outcomes and an increased mortality rate (3) .
Gentamicin induced nephrotoxicity is usually assessed by the monitoring of the change in serum creatinine in patients (4) . The risk, injury, failure, loss, end-stage renal disease (RIFLE) criteria proposed by the acute dialysis quality initiative (ADQI) group classifies acute renal dysfunction in five different classes, namely: R (Risk), I (injury), F (failure), L (loss) and E (end-stage kidney disease) and has been used to monitor acute change in renal function during gentamicin therapy (5) .
Complementary to the monitoring of the serum creatinine is the therapeutic drug monitoring (TDM) of serum gentamicin level, TDM facilitates the assessment of the peak serum gentamicin level which is the indicator of its efficacy, while the trough level is implicated in the toxic effect (6, 7) . The measurement of the drug levels in the serum and the application of pharmacokinetic principles have greatly improved patient care. Positive results, such as decreased nephrotoxicity, reduced length of hospital stays and improved clinical response with a decrease in the number of days with signs of infection have been reported (8, 9) . However, other current studies have suggested that TDM may not be of additional clinical benefit in all patients. It has been suggested that TDM of gentamicin in critically ill patients is not required if the renal function is normal. But it is required if there is concomitant nephrotoxic drugs administration, if the patient is ≥ 60 years, if there are other co-morbidities (eg cardiovascular diseases and diabetes mellitus) or if therapy is longer than five days (10, 11) .
In the settings where TDM is not available, the assessment of serum creatinine is important to ensure the safe use of aminoglycoside. The reliance on serum creatinine only requires monitoring every other day (10) . This study examined the frequency of nephrotoxicity among adult patients receiving intravenous gentamicin at the University Hospital of the West Indies (UHWI) and the presence of the common risk factors known to be associated with gentamicin induced nephrotoxicity.
METHODS
This study was reviewed and approved by the University Hospital of the West Indies/The University of the West Indies/Faculty of Medical Science/Ethic Committee (ECP 271, 12/13, June 17, 2013). The patients admitted to the UHWI who received gentamicin therapy between July 2013 and July 2014 were eligible for study. The inclusion criteria for the study include: patients 18 years and older, who were administered gentamicin through intravenous infusion and consented to be part of the study. The patients receiving only a single dose of intravenous gentamicin and renal dialysis patients were excluded. Information was recorded regarding the patients' demographics (age, gender and weight), the indication for gentamicin use, and gentamicin dose and treatment period. Serum creatinine levels were assayed in the Chemical Pathology Department at the UHWI using the Cobas 6000 C510 Spectrometer. The baseline creatinine was recorded as the minimum of the first-three serum creatinine determinations upon the patients' admission, before the initiation of gentamicin therapy (3). The peak serum creatinine was recorded as the highest value during gentamicin treatment.
Nephrotoxicity was assessed using serum creatinine as defined by the RIFLE criteria, defined as serum creatinine increases of at least 1.5 times the baseline value (12) . The presence of the risk factors associated with nephrotoxicity was also assessed. Discrete variables were reported as counts with percentages; continuous data were expressed as means and standard deviations (SDs) and median (with range) unless otherwise stated. The Wilcoxon-test was used for inferential statistics paired comparison with p < 0.05 considered as significant. The data was analysed using the Statistical Package for the Social Sciences (SPSS) version 20.0.
RESULTS
Eleven patients participated in this study. Six (54.5%) of them were males; their median age was 51 years (range: 33-84). The weights of nine (82%) of the patients were recorded; the median was 62.9 kg, (range 51.7 to 75.1 kg). All the patients had at least one chronic disease condition including cardiovascular disease, diabetes mellitus, acute myeloid leukemia, acquired immunodeficiency syndrome, hypothyroidism and gouty arthritis (Table 1) . Sepsis (82%) was the most common indication among the patients in this study. The specific indications reported were: septic shock due to a lower respiratory tract infection (11%), neutropenic sepsis (33%), hospital acquired pneumonia and urosepsis (11%), sepsis due to infected decubitus ulcer (11%), intra-abdominal sepsis (11%) and septicemia (11%). The causative organisms were isolated from the blood and/or urine samples for eight (73%) of the patients. Among the isolated bacteria were: Pseudomonas aeruginosa, Coagulase negative staphylococcus, Klebsiella pneumoniae, Staphylococcus aureus, Escherichia Coli and Enterococus sp.
Eight (73%) of the patients initially received gentamicin as empiric therapy and three (27%) received therapy after microorganism identification. However, most of the isolated bacteria (91%) were confirmed to be sensitive to gentamicin. The data on dosing are summarized in Table 2 along with the serum creatinine data. For dosing, the dose regimen most often employed was the multiple daily dosing regimen (73%) with a median dose of 160 mg/day (50-240 mg/day). Median treatment duration was eight days (5-30 days). The median serum creatinine at the baseline was 56 µmol/L (range: 22-94 µmol/L), and the median peak serum creatinine was 78 µmol/L (range: 45-316 µmol/L).
There was a significant rise in the patients' serum creatinine value from the baseline to peak during gentamicin therapy (p < 0.01). All the patients had serum creatinine assayed at least twice within five days. Eight of the patients had an increase in serum creatinine within five days from the start of gentamicin therapy and six (55%) of the patients experienced a peak serum creatinine of ≥ 1.5 times the baseline value. The median time interval from first gentamicin dose to peak serum creatinine was seven days (3 to 11 days).
The frequency of the risk factors that predispose patients to nephrotoxicity secondary to gentamicin therapy was assessed. Among the risk factors recorded, nine (82%) of the patients were concomitantly administered at least one drug that is known to be nephrotoxic or likely to potentiate the nephrotoxicity of gentamicin. They included: ibuprofen, aspirin, lisinopril, furosemide, vancomycin, cefuroxime and ceftriaxone. Multiple daily dosing and a prolonged duration of therapy (> 5 days) were each evident in eight (73%) and ten (91%) of the patients, respectively. Five (45%) of the patients were 60 years or older.
Five (45%) of the patients died, four (36%) of the surviving patients were cured of bacterial infection and two (18%) had a remaining infection at the end of gentamicin therapy. Infection was listed among the cause of death in three (60%) of the five fatalities. Of these three patients, one fatality occurred shortly after treatment failure due to gentamicin-resistant Klebsiella pneumonia. The other reported fatalities were documented as due to the co-morbid states previously mentioned.
Of the six patients who experienced nephrotoxicity, two had fatal outcomes. Renal impairment was not listed as cause of death in any of the two patients. The remaining patients showed a gradual decrease in serum creatinine values after their completion of gentamicin therapy. Based on the physician's recommendation, gentamicin was discontinued for one patient before the end of the prescribed treatment. This was in view of documented renal failure which developed 11 days after the initiation of gentamicin therapy. The percentage increase in serum creatinine in this patient was 166%. The serum creatinine value, however, also trended towards the baseline values after the discontinuation of the gentamicin therapy.
DISCUSSION
The focus of this study was to evaluate the safety of intravenous gentamicin therapy in patients in the absence of TDM. All the patients had baseline serum creatinine within the normal range, thus suggesting normal renal function prior to the start of gentamicin. The gentamicin dosage received by these patients ranged from 50 to 240 mg/day and are consistent with the therapy in established guidelines. The monitoring of serum creatinine changes every other day was also consistent with the current guidelines for gentamicin therapy. Most of the patients, 55%, had a peak creatinine concentration of 1.5 times or more which was attained in 5 to 11 days on gentamicin therapy, suggesting that some levels of nephrotoxicity occurred in most of the patients given intravenous gentamicin at UHWI. Additionally, for this study, the median period of treatment was eight days (5-30 days) and the median time to reach peak serum creatinine was seven days (3-11 days). Our findings therefore support previous evidence of the risk of gentamicin induced nephrotoxicity occurring within five days from the start of therapy (10) .
It is recommended that TDM of aminoglycosides, such as gentamicin is advised under the following conditions: when there renal dysfunction; there are difficultto-treat infections; there is a prolonged duration of therapy; patients are on concomitant nephrotoxic medications and in patients of at least 60 years or if there are other co-morbidities [eg cardiovascular disease or diabetes mellitus] (11). All the patients in this study had at least one comorbid disease including hypertension and diabetes mellitus and most were on a concurrent drug with the potential to increase nephrotoxic risk including non-steroidal anti-inflammatory drugs and other antibacterials, such as vancomycin (13) . The ageing renal physiology combined with the increasing co-morbidities and severity of disease, as well as multiple drug use, makes this sample at even greater risk for gentamicin induced nephrotoxicity (14) . With the presence of at least one of these factors in each patient, the study suggests that although patients displayed normal renal function at the baseline, all the patients could have benefited from TDM to reduce the risk of nephrotoxicity occurring.
Multiple daily dosage is also known to likely predispose patients to nephrotoxicity than once daily dosage (13, 15) . With most of the patients on multiple daily dosage (73%) therapy rather than the once daily dose, the patients were at a greater risk of nephrotoxicity. In the absence of TDM, the careful monitoring of serum creatinine as a marker of renal function must be ensured and in the presence of evidence of renal changes, a review of drug regimen is indicated.
The findings of this study utilized the use of the serum creatinine as the only determinant of gentamicin induced nephrotoxicity. The causal relationship with gentamicin use would have been more definitive with the measurement of gentamicin serum levels. Additionally, the small sample size did not facilitate the actual calculation of the associations with the known risk factors for gentamicin induced nephrotoxicity.
CONCLUSION
Gentamicin remains important especially for the treatment of serious gram negative infections despite its known potential for nephrotoxicity. With more than half of the patients in this study experiencing some levels of nephrotoxicity within five days of the start of therapy, the evaluation of the other risk factors present in each patient should be considered. Adhering to established guidelines, especially in the absence of TDM may reduce nephrotoxicity's risk.
